Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Entrada Therapeutics issues time-based RSU and stock option inducement awards to eight new hires under its 2025 Inducement Equity Plan.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Entrada Therapeutics (TRDA) granted equity inducement awards to eight newly hired non-executive employees under its 2025 Inducement Equity Plan, effective September 1, 2026.
The awards comprise an aggregate of 61,365 RSUs and options to purchase 19,425 shares of common stock, with an exercise price of $7.07 per share, equal to the closing price on August 31, 2026. The Compensation Committee approved these grants as a material inducement to employment under Nasdaq Listing Rule 5635(c)(4).
Options vest 25% on the first anniversary of the vesting commencement date and 75% in 36 equal monthly installments thereafter, fully vesting on the fourth anniversary, subject to continued employment. RSUs vest 25% after one year and 6.25% quarterly on March 1, June 1, September 1 and December 1, subject to continuous service, all under the plan and award agreements.
Details
News Market Reaction – TRDA
On Sep 3, the first trading day after this news, TRDA closed 1.78% below the previous close.
Data tracked by StockTitan Argus for the Sep 3 session.
Key Figures
- Restricted stock units
- 61,365 RSUs
- Granted to newly hired employees
- Option shares
- 19,425 shares
- Shares underlying inducement options
- Recipients
- 8 newly-hired non-executive employees
- Inducement grants
- Option exercise price
- $7.07 per share
- Equal to the August 31, 2026 closing price
- Grant effective date
- September 1, 2026
- Inducement Plan grants
- Option vesting
- 25% at one year; 75% in 36 monthly installments
- Subject to continued employment
- RSU vesting
- 25% at one year; 6.25% quarterly thereafter
- Subject to continuous service
Historical Context
-
Lower collaboration revenue and net loss accompanied cash runway into third quarter 2027.
-
Committee recommended a 10 mg/kg Cohort 2 dose after reviewing eight participants.
-
Company granted 18,600 RSUs to three newly hired non-executive employees.
-
Positive topline DMD data accompanied quarterly results and additional planned readouts.
-
Cohort 1 reported favorable safety and biomarker changes, but juvenile pharmacokinetics were lower.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
restricted stock units financial
nasdaq listing rule 5635(c)(4) regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that the Company granted an aggregate of 61,365 restricted stock units (“RSUs”) and options to purchase 19,425 shares of the Company’s common stock to eight newly-hired non-executive employees under the Company’s 2025 Inducement Equity Plan (the “Inducement Plan”), effective as of September 1, 2026. The options have an exercise price of
One-fourth of the shares underlying each employee’s option will vest on the one-year anniversary of the vesting commencement date and thereafter the remaining
About Entrada Therapeutics
Entrada Therapeutics is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of genetic medicines that engage intracellular targets that have long been considered inaccessible. Through proprietary, versatile and modular approaches, Entrada is advancing a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases, among others. The Company’s lead oligonucleotide programs are in development for the potential treatment of people living with Duchenne muscular dystrophy who are exon 44, 45, 50 and 51 skipping amenable. Entrada has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
For more information about Entrada, please visit our website, www.entradatx.com, and follow us on LinkedIn.
Investor Contact
Doug Snow
Head of Investor Relations
dsnow@entradatx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What equity inducement awards did Entrada Therapeutics (TRDA) grant in September 2026?
Entrada Therapeutics granted an aggregate of 61,365 restricted stock units and options to purchase 19,425 shares of common stock to eight newly hired non-executive employees, effective September 1, 2026, under its 2025 Inducement Equity Plan.
What is the exercise price of the new Entrada Therapeutics (TRDA) stock options?
The newly granted options have an exercise price of $7.07 per share, which equals the closing price of Entrada Therapeutics common stock on August 31, 2026.
How do the stock options granted by Entrada Therapeutics (TRDA) vest for new employees?
For each employee, 25% of the option shares vest on the one-year anniversary of the vesting commencement date. The remaining 75% vest in 36 equal monthly installments, so the options fully vest on the fourth anniversary, subject to continued employment.
What is the vesting schedule for the RSUs granted by Entrada Therapeutics (TRDA)?
For the RSUs, 25% vest on the one-year anniversary of the vesting commencement date. Thereafter, 6.25% vest quarterly on March 1, June 1, September 1 and December 1 each year, subject to the employee’s continuous service.
Under which plan were the new Entrada Therapeutics (TRDA) inducement grants made?
The RSUs and stock options were granted under the company’s 2025 Inducement Equity Plan, which was approved by the Board of Directors in March 2025, and are subject to related award agreements.
Why were these Entrada Therapeutics (TRDA) equity awards structured as inducement grants?
The Compensation Committee approved the grants as a material inducement to the new employees’ entry into employment with Entrada Therapeutics, in accordance with Nasdaq Listing Rule 5635(c)(4).